MA71689A - Inhibiteurs de l'inflammasome nlrp3 - Google Patents
Inhibiteurs de l'inflammasome nlrp3Info
- Publication number
- MA71689A MA71689A MA71689A MA71689A MA71689A MA 71689 A MA71689 A MA 71689A MA 71689 A MA71689 A MA 71689A MA 71689 A MA71689 A MA 71689A MA 71689 A MA71689 A MA 71689A
- Authority
- MA
- Morocco
- Prior art keywords
- nlrp3 inflammasome
- inflammasome inhibitors
- inhibitors
- nlrp3
- inflammasome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263370300P | 2022-08-03 | 2022-08-03 | |
| CN2023097282 | 2023-05-30 | ||
| EP23755486.0A EP4565326A1 (fr) | 2022-08-03 | 2023-08-02 | Inhibiteurs de l'inflammasome nlrp3 |
| PCT/IB2023/057819 WO2024028782A1 (fr) | 2022-08-03 | 2023-08-02 | Inhibiteurs de l'inflammasome nlrp3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71689A true MA71689A (fr) | 2025-05-30 |
Family
ID=87580191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71689A MA71689A (fr) | 2022-08-03 | 2023-08-02 | Inhibiteurs de l'inflammasome nlrp3 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20240067627A1 (fr) |
| EP (1) | EP4565326A1 (fr) |
| JP (1) | JP7881051B2 (fr) |
| KR (1) | KR20250043519A (fr) |
| CN (2) | CN119677725A (fr) |
| AR (1) | AR130094A1 (fr) |
| AU (2) | AU2023318764B2 (fr) |
| CA (1) | CA3262660A1 (fr) |
| CL (1) | CL2025000285A1 (fr) |
| CO (1) | CO2025002057A2 (fr) |
| CR (1) | CR20250063A (fr) |
| DO (1) | DOP2025000013A (fr) |
| IL (1) | IL318533A (fr) |
| JO (1) | JOP20250023A1 (fr) |
| MA (1) | MA71689A (fr) |
| MX (1) | MX2025001273A (fr) |
| PE (1) | PE20251255A1 (fr) |
| TW (1) | TW202406550A (fr) |
| UY (1) | UY40374A (fr) |
| WO (1) | WO2024028782A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
| WO2026057634A1 (fr) * | 2024-09-11 | 2026-03-19 | Sanofi | Forme cristalline d'un inhibiteur nlrp3 de pyridazine |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2510997A1 (fr) | 1981-08-10 | 1983-02-11 | Sanofi Sa | Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant |
| PT93060B (pt) | 1989-02-07 | 1995-12-29 | Sanofi Sa | Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem |
| FR2663326B2 (fr) | 1989-11-17 | 1992-10-16 | Sanofi Sa | Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant. |
| FR2676444B1 (fr) | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| WO2004078163A2 (fr) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| EP1745039A4 (fr) | 2004-05-08 | 2009-07-22 | Neurogen Corp | Pyridazines 3-aryl-5,6-disubstituees |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| WO2008058064A1 (fr) | 2006-11-07 | 2008-05-15 | Lexicon Pharmaceuticals, Inc. | Composés multicycliques liés à une amine et leurs méthodes d'utilisation |
| GB0720444D0 (en) | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
| WO2010048149A2 (fr) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie |
| WO2010128152A1 (fr) | 2009-05-07 | 2010-11-11 | Novartis Ag | C-glycosides hétérocycliques condensés pour le traitement du diabète |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| KR20120087950A (ko) | 2009-10-20 | 2012-08-07 | 노파르티스 아게 | 글리코시드 유도체 및 그의 용도 |
| ES2622138T3 (es) | 2010-06-23 | 2017-07-05 | Hanmi Science Co., Ltd. | Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa |
| WO2012016133A2 (fr) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 |
| PH12013500246A1 (en) | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| US8835472B2 (en) | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| EP2651405A2 (fr) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Inhibiteurs de caséine kinase 1 (ck1 ) |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| US9073947B2 (en) | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| EP2858500A4 (fr) | 2012-06-08 | 2016-04-06 | Biogen Ma Inc | Inhibiteurs de la tyrosine kinase de bruton |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| WO2014085474A1 (fr) | 2012-11-28 | 2014-06-05 | Intercept Pharmaceuticals, Inc. | Traitement d'une maladie pulmonaire |
| UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| SG11201603026PA (en) | 2013-11-05 | 2016-05-30 | Novartis Ag | Compositions and methods for modulating farnesoid x receptors |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| EP3076974A1 (fr) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Association thérapeutique d'un inhibiteur de pi3k et d'un inhibiteur de btk |
| TN2016000127A1 (en) | 2013-12-20 | 2017-10-06 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors. |
| WO2015110923A2 (fr) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| HRP20241236T1 (hr) | 2014-05-13 | 2024-12-06 | Novartis Ag | Spojevi i pripravci za induciranje hondrogeneze |
| CN103965169A (zh) | 2014-05-30 | 2014-08-06 | 彭正中 | 一种化合物及其制备方法与用途 |
| WO2016022626A1 (fr) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antagonistes hétérocycliques des récepteurs cgrp |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| MX393057B (es) | 2014-10-24 | 2025-03-24 | Bristol Myers Squibb Co | Compuestos de indol carboxamida útiles como inhibidores de cinasas. |
| CN107427468B (zh) | 2014-12-24 | 2022-02-25 | 普林斯匹亚生物制药公司 | Btk抑制剂的部位特异性给药 |
| ES2907461T3 (es) | 2015-01-20 | 2022-04-25 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos |
| US20180008629A1 (en) | 2015-01-29 | 2018-01-11 | Yale University | Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders |
| EP3256126B1 (fr) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Composés pour le traitement du cancer |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| EP3912979B1 (fr) | 2015-06-03 | 2026-03-25 | Principia Biopharma Inc. | Inhibiteurs de kinase de tyrosine |
| MA42510A (fr) | 2015-06-10 | 2018-06-06 | Biogen Ma Inc | Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton |
| EP3359159B1 (fr) | 2015-10-09 | 2023-06-07 | ACEA Therapeutics, Inc. | Compositions pharmaceutiques d'un inhibiteur pyrrolopyrimidine de kinases, et leurs procédés de préparation |
| TW202510883A (zh) | 2015-11-04 | 2025-03-16 | 德商默克專利有限公司 | 使用具有btk抑制活性之嘧啶及吡啶化合物治療癌症之方法 |
| CA3119019C (fr) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Composes et methodes pour traiter la maladie de huntington |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| ES2875384T3 (es) | 2016-01-05 | 2021-11-10 | Jiangsu Hengrui Medicine Co | Forma cristalina del inhibidor de la quinasa BTK y método de preparación del mismo |
| CN109071524A (zh) | 2016-01-15 | 2018-12-21 | 布里格姆及妇女医院股份有限公司 | 作为eaat2活化剂的哒嗪衍生物 |
| KR101865120B1 (ko) | 2016-06-29 | 2018-06-08 | 숭실대학교 산학협력단 | 테스트 노드 기반의 무선 측위 방법 및 그 장치 |
| IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
| EP3272739A1 (fr) | 2016-07-20 | 2018-01-24 | NodThera Limited | Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1 |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| ES3002968T3 (en) | 2017-07-14 | 2025-03-10 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| US20230152257A1 (en) | 2017-09-25 | 2023-05-18 | Skyhawk Therapeutics, Inc. | Methods and compositions for screening and identification of splicing |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| JP2021521200A (ja) | 2018-04-10 | 2021-08-26 | スカイホーク・セラピューティクス・インコーポレーテッド | 癌の処置のための化合物 |
| SG11202104495YA (en) | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| CN115279739B (zh) * | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | 取代哒嗪化合物 |
| US20230348437A1 (en) * | 2020-07-02 | 2023-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| TW202231281A (zh) | 2020-12-25 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一類含噠嗪的化合物及其醫藥用途 |
| EP4289823A4 (fr) * | 2021-02-08 | 2025-02-26 | Medshine Discovery Inc. | Dérivés de pyridazine phénol substitués |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
-
2023
- 2023-07-27 UY UY0001040374A patent/UY40374A/es unknown
- 2023-08-01 US US18/363,207 patent/US20240067627A1/en active Pending
- 2023-08-01 TW TW112128876A patent/TW202406550A/zh unknown
- 2023-08-01 AR ARP230102029A patent/AR130094A1/es unknown
- 2023-08-02 IL IL318533A patent/IL318533A/en unknown
- 2023-08-02 PE PE2025000269A patent/PE20251255A1/es unknown
- 2023-08-02 KR KR1020257006563A patent/KR20250043519A/ko active Pending
- 2023-08-02 CN CN202380056099.4A patent/CN119677725A/zh active Pending
- 2023-08-02 CR CR20250063A patent/CR20250063A/es unknown
- 2023-08-02 JP JP2025505788A patent/JP7881051B2/ja active Active
- 2023-08-02 WO PCT/IB2023/057819 patent/WO2024028782A1/fr not_active Ceased
- 2023-08-02 EP EP23755486.0A patent/EP4565326A1/fr active Pending
- 2023-08-02 CA CA3262660A patent/CA3262660A1/fr active Pending
- 2023-08-02 CN CN202610038086.XA patent/CN121873039A/zh active Pending
- 2023-08-02 AU AU2023318764A patent/AU2023318764B2/en active Active
- 2023-08-02 MA MA71689A patent/MA71689A/fr unknown
-
2024
- 2024-10-16 US US18/917,653 patent/US12378222B2/en active Active
-
2025
- 2025-01-29 DO DO2025000013A patent/DOP2025000013A/es unknown
- 2025-01-30 JO JOJO/P/2025/0023A patent/JOP20250023A1/ar unknown
- 2025-01-30 CL CL2025000285A patent/CL2025000285A1/es unknown
- 2025-01-30 MX MX2025001273A patent/MX2025001273A/es unknown
- 2025-02-25 CO CONC2025/0002057A patent/CO2025002057A2/es unknown
-
2026
- 2026-06-30 AU AU2026205161A patent/AU2026205161A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025000285A1 (es) | 2025-06-13 |
| UY40374A (es) | 2024-02-15 |
| AU2023318764B2 (en) | 2026-04-23 |
| TW202406550A (zh) | 2024-02-16 |
| IL318533A (en) | 2025-03-01 |
| CA3262660A1 (fr) | 2024-02-08 |
| KR20250043519A (ko) | 2025-03-28 |
| WO2024028782A1 (fr) | 2024-02-08 |
| AU2023318764A1 (en) | 2025-01-09 |
| CR20250063A (es) | 2025-03-27 |
| AU2026205161A1 (en) | 2026-07-16 |
| PE20251255A1 (es) | 2025-05-06 |
| DOP2025000013A (es) | 2025-02-28 |
| MX2025001273A (es) | 2025-03-07 |
| JP2025525866A (ja) | 2025-08-07 |
| US20250034114A1 (en) | 2025-01-30 |
| US12378222B2 (en) | 2025-08-05 |
| CO2025002057A2 (es) | 2025-03-06 |
| US20240067627A1 (en) | 2024-02-29 |
| CN121873039A (zh) | 2026-04-17 |
| CN119677725A (zh) | 2025-03-21 |
| JOP20250023A1 (ar) | 2025-01-30 |
| EP4565326A1 (fr) | 2025-06-11 |
| JP7881051B2 (ja) | 2026-06-26 |
| AR130094A1 (es) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4577550A4 (fr) | Nouveaux inhibiteurs de l'inflammasome nlrp3 | |
| MA53388A (fr) | Inhibiteurs d'inflammasome nlrp3 | |
| DK4363406T3 (da) | Nlrp3-inflammasomhæmmere | |
| IL315027A (en) | Inhibitors of nlrp3 | |
| DK4337652T3 (da) | NLRP3-hæmmere | |
| EP4251630A4 (fr) | Inhibiteurs d'inflammasome de nlrp3 sulfonylurée | |
| IL287042A (en) | Inflammatory inhibitors of nlrp3 | |
| EP4563151A4 (fr) | Composition pharmaceutique comprenant un inhibiteur de kras g12d | |
| EP4362946A4 (fr) | Modulateurs de nlrp3 | |
| IL318533A (en) | NLRP3 inflammasome inhibitors | |
| IL306022A (en) | NLRP3 inflammasome inhibitors | |
| EP4129996A4 (fr) | Nouvel inhibiteur aminopyrimidine d'egfr | |
| EP3999045A4 (fr) | Composés en tant qu'inhibiteurs d'inflammasome de nlrp3 et compositions et utilisations de ceux-ci | |
| IL315592A (en) | Nlrp3 modulators | |
| MX2025011086A (es) | Inhibidores de inflamasoma nlrp3 y usos de los mismos | |
| EP4217346C0 (fr) | Modulateurs du nlrp3 | |
| ITFI20050239A1 (it) | Idrossammati come inibitori dell'istone deacetilasi e formulazioni farmaceutiche che li contegono | |
| SMT202500216T1 (it) | Composti e composizioni come inibitori di sppl2a | |
| EP1829864A4 (fr) | Derives d'isoquiline utiles en tant qu'inhibiteurs de la calpaine | |
| TH2401005270A (th) | ตัวยับยั้งของ nlrp3 | |
| IT202200008321A1 (it) | Composti tetraidroisochinolinici come inibitori dell’inflammasoma nlrp3 e loro uso come medicamenti | |
| HK40122493A (zh) | Nlrp3发炎小体抑制剂 | |
| HK40128873A (en) | Novel nlrp3 inflammasome inhibitors | |
| IT202200008246A1 (it) | Composti solfonammidici come inibitori dell’inflammasoma nlrp3 e loro uso come medicamenti | |
| IL326491A (en) | Nlrp3 inflammasome inhibitor and use thereof |